New insights into fatty liver disease. Rob Goldin Centre for Pathology, Imperial College

Similar documents
Liver Pathology in the 0bese

Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need?

Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need?

Steatotic liver disease

Challenges in the Diagnosis of Steatohepatitis

Non-Alcoholic Fatty Liver Disease An Update

Liver biopsy as the gold standard for diagnosis. Pierre BEDOSSA

AAIM: GI Workshop Follow Up to Case Studies. Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease

PHC, Paris, 30th Jan 2017 PATHOLOGY OF NAFLD. Pierre Bedossa. Departement of Pathology Hôpital Beaujon University Paris-Diderot Paris - FRANCE

Enterprise Interest Nothing to declare

Linda Ferrell, MD Distinguished Professor Vice Chair Director of Surgical Pathology Dept of Pathology

in liver pathology? 2014 What s hot

Pathology of Fatty Liver Disease

Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy

NAFLD/NASH. Definitions. Pathology NASH. Vicki Shah PA-C, MMS Rush University Hepatology

DIAGNOSIS OF NASH LIVER BIOPSY. PHC

Updates from the AASLD

Nonalcoholic Fatty Liver Disease: Definitions, Risk Factors, and Workup

AASLD: Boston Rob Goldin

Improving Access to Quality Medical Care Webinar Series

Non-Alcoholic Fatty Liver Diseasean underestimated epidemic

Update on Non-Alcoholic Fatty Liver Disease. Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI

Index. Note: Page numbers of article titles are in boldface type.

NAFLD & NASH: Russian perspective

NONALCOHOLIC FATTY LIVER DISEASE. Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD. April 13, 2012

(C) Fig 5.1 Classical non alcoholic steatohepatitis (NASH). (A) Steatosis, hepatocyte ballooning, and inflammation (the trio of changes

M30 Apoptosense ELISA. A biomarker assay for detection and screening of NASH

British Liver Transplant Group Pathology meeting September Leeds cases

Use of Ultrasound in NAFLD

Making the best use of liver biopsy: clinical perspective. Steve Ryder Wolfson Digestive Diseases Centre University of Nottingham

FATTY LIVER DISEASE (NAFLD) (NASH) A GROWING

Pathology of Non-Alcoholic Fatty Liver Disease

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC

Non alcoholic fatty liver and Non alcoholic Steatohepatitis. By Dr. Seham Seif

Invited Re vie W. Analytical histopathological diagnosis of small hepatocellular nodules in chronic liver diseases

Preliminary clinical experience with Shear Wave Dispersion Imaging for liver viscosity

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC

Pitfalls in the diagnosis of well-differentiated hepatocellular lesions

NON-ALCOHOLIC STEATOHEPATITIS AND NON-ALCOHOLIC FATTY LIVER DISEASES

Conflicts of Interest in the last 12 months

Management of alcoholic hepatitis: Implications for options beyond the STOPAH study

Evaluation of Liver Mass Lesions. American College of Gastroenterology 2013 Regional Postgraduate Course

First European NAFLD-NASH Summit European Parliament, Brussels, May 31 st NAFLD/NASH : an expanding burden on liver health

Normal ALT for men 30 IU/L 36% US males abnormal. Abnl ALT. Assess alcohol use/meds. Recheck in 6-8 weeks. still pos

Early life determinants of Non-Alcoholic Fatty Liver Disease and NASH DR JULIANA MUIVA-GITOBU KENYA PAEDIATRIC ASSOCIATION CONFERENCE APRIL 2016.

Nonalcoholic Fatty Liver Disease: Pros and Cons of Histologic Systems of Evaluation

Novel multiparametric magnetic resonance elastography (MRE) protocol accurately predicts NAS score for NASH diagnosis

Advances in Understanding Hepatic Fibrosis and Chronic Liver Disease

Biliary tract diseases of the liver

Non-Alcoholic Fatty Liver Disease

PEDIATRIC FOIE GRAS: NON-ALCOHOLIC FATTY LIVER DISEASE

LIVER PATHOLOGY. Thursday 28 th November 2013

NASH : Diagnosis and investigation. VII Workshop international, Curitiba, Brazil 29/08/2014

CHAPTER 1. Alcoholic Liver Disease

HEPATOCYTE SPECIFIC CONTRAST MEDIA: WHERE DO WE STAND?

LIVER PATHOLOGY. Thursday 28 th November 2013

Clinical Trials & Endpoints in NASH Cirrhosis

PREVALENCE OF NAFLD & NASH

Original Article. Significance of Hepatic Steatosis in Chronic Hepatitis B Infection INTRODUCTION

Dietary supplementation in treating non-alcoholic fatty liver disease Dr. Ahmad Saedi Associate Professor School of Nutritional Sciences and

Liver, Liver Fat, Fibrosis and HCC Screening with DECT

HEPATOCELLULAR CARCINOMA: AN OVERVIEW

Hepatocellular Adenomas: Genetics & Imaging Update 2017

Nonalcoholic Fatty Liver Disease in Children: Typical and Atypical

Prognosis of NASH VII Workshop Intenracional de Actualizaçao em Hepatologia, Aug 29th 2014

«STEATOSI EPATICA ED EPATOPATIE METABOLICHE» Ester Vanni Division of Gastroenterology University of Turin

Exploring a Link Between Spy1 and Hepatocellular Carcinoma Progression

Role of Liver Biopsy. Role of Liver Biopsy 9/3/2009. Liver Biopsies in Viral Hepatitis: Beyond Grading and Staging

Pancreatic exocrine insufficiency: a rare cause of nonalcoholic steatohepatitis

PITFALLS IN THE DIAGNOSIS OF MEDICAL LIVER DISEASE WITH TWO CONCURRENT ETIOLOGIES I HAVE NOTHING TO DISCLOSE CURRENT ISSUES IN ANATOMIC PATHOLOGY 2017

Hepatitis C wi w t i h Ju J dy y W y W a y t a t t

Fatty Liver- how important is it? Jeremy F.L. Cobbold MA PhD MRCP Clinical Lecturer in Hepatology Imperial College London

WORLDWIDE EPIDEMIOLOGY OF NASH

Jesse Civan, M.D. Medical Director, Jefferson Liver Tumor Center

Why to biopsy? Indications for liver biopsy in common medical liver diseases- how are they changing?

Alastair Burt Newcastle University

Autoimmune Liver Diseases

Slide 7 demonstrates acute pericholangitisis with neutrophils around proliferating bile ducts.

Liver Fat Quantification

Interobserver Agreement on Pathologic Features of Liver Biopsy Tissue in Patients with Nonalcoholic Fatty Liver Disease

University of Groningen. Non-alcoholic fatty liver disease Sheedfar, Fareeba

End Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC

End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC

LIVER IMAGING TIPS IN VARIOUS MODALITIES. M.Vlychou, MD, PhD Assoc. Professor of Radiology University of Thessaly

Hepatocellular Carcinoma (HCC): Burden of Disease

Autoimmune Hepatitis Events Easl

Liver Pathology Symposium - medical livers

UC SF. Liver and Gastrointestinal Pathology Update. University of California San Francisco. September 3, 2009

V8 NEXUS. Glyco Liver Profile NA2 NA3 NA2FB NGA2F. The next generation in non-invasive liver diagnostics INFLAMMATION FIBROSIS CIRRHOSIS HCC

Nonalcoholic fatty liver disease (NAFLD) is the most common

EDITOR S PICK NON-ALCOHOLIC FATTY LIVER DISEASE - CHANGING THE PREVALENCE OF LIVER CANCER?

PATHOLOGY OF LIVER TUMORS

UMHS-PUHSC JOINT INSTITUTE

ACP-BSG meeting The liver in systemic inflammatory disorders. Dr Adrian C Bateman Southampton University Hospitals NHS Trust

Steatohepatitic Hepatocellular Carcinoma, a Morphologic Indicator of Associated Metabolic Risk Factors

Bariatric Surgery and Liver Transplantation

Pathology of fatty liver: differential diagnosis of non-alcoholic fatty liver disease

Liver Ultrasound - Beyond the Basics. Pamela Parker Lead Sonographer

DILI PATHOLOGY. PHILIP KAYE November 2017 BSG Pathology Winter Meeting

Steatosis/Steatohepatitis

Transcription:

New insights into fatty liver disease Rob Goldin Centre for Pathology, Imperial College r.goldin@imperial.ac.uk

Prevalence of NASH Global prevalence of NAFLD is 25% with highest prevalence in the Middle East and South America and lowest in Africa. Global epidemiology of nonalcoholic fatty liver Hepatology. 2016 Jul;64(1):73-84.

Global epidemiology of nonalcoholic fatty liver disease Meta analytic assessment of prevalence, incidence, and outcomes Hepatology Volume 64, Issue 1, pages 73-84, 22 FEB 2016 DOI: 10.1002/hep.28431 http://onlinelibrary.wiley.com/doi/10.1002/hep.28431/full#hep28431-fig-0003

WHO. European Status Report on Alcohol and Health: World Health Organization. Regional Office for Europe; 2010.

Distinction of alcoholic liver disease from non-alcoholic liver disease Clinical features Alcohol intake: less than 10g/day in women, 20 g/day in men Blood tests Imaging Histology

Alcohol production in NASH Dysbiosis might increase intestinal ethanol production; for example, 1 g of Escherichia coli can produce 0.8 g of ethanol per hour in anaerobic conditions The ob/ob mice that develop NASH have higher early-morning breath alcohol content compared with their lean littermates Elevated blood ethanol levels have also been observed in patients with NASH Ethanol produced in the gut might contribute to liver injury by increasing intestinal permeability and portal LPS levels The role of the gut microbiota in NAFLD Nature Reviews Gastroenterology & Hepatology 13, 412 425 (2016)

Histological features common to ASH and NASH Large droplet fatty change Inflammation, lobular or portal Ballooning +/ Mallory Denk bodies Fibrosis Apoptotic hepatocytes Megamitochondria

Differences between ASH and NASH The unique zone 1 borderline injury pattern of pediatric fatty liver disease does not have a corresponding injury pattern in alcoholic liver disease. The following are commoner in ASH: diffuse microvesicular steatosis, cholestasis neutrophilic satellitosis of Mallory Denk body containing balloon cells dense networks of perisinusoidal fibrosis Only ASH shows a significant incidence of veno occlusive lesions and sclerosing hyaline necrosis. When is it NAFLD and when is it ALD? Clinical Dilemmas in NAFLD Elsevier 2016 p 72

Nuclear Vacuolation

Physiological hepatic nuclear vacuolation is common in the 20s and persists into the 30s Physiological hepatic nuclear vacuolation-how long does it persist? Histopathology. 2010 Mar;56(4):426-9.

Non-Alcoholic Liver Disease

NAFLD Activity Score Steatosis grade Lobular inflammation Hepatocellular ballooning 0: <5% 0: None 0: None 1: 5-33% 1:<2 foci/20x field 1: Mild, few 2: 34-66% 2: 2-4 foci/20x field 2: Moderate marked, 3: >66% 3: >4 foci/20x field many NAFLD activity score (NAS): 0-8 Steatosis (0-3) + Lobular Inflammation (0-3) + Ballooning (0-2) The NAS and the Histopathologic Diagnosis in NAFLD: Distinct Clinicopathologic The NAS and Meanings. The Histopathologic Hepatology. 2011 Diagnosis Mar; 53(3): in NAFLD: 810 820. Distinct Clinicopathologic Meanings. Hepatology. 2011 Mar; 53(3): 810 820.

NAFLD Activity Score The diagnosis of nonalcoholic steatohepatitis (NASH) is defined by the presence and pattern of specific histological abnormalities on liver biopsy. A separate system of scoring the features of nonalcoholic fatty liver disease called the NAFLD Activity Score (NAS) was developed as a tool to measure changes in NAFLD during therapeutic trials. However, some studies have used threshold values of the NAS, specifically NAS 5, as a surrogate for the histologic diagnosis of NASH. The NAS and the Histopathologic Diagnosis in NAFLD: Distinct Clinicopathologic Meanings. Hepatology. 2011 Mar; 53(3): 810 820.

What is ballooning?

Ballooning and lobular inflammation grading. B) Normal hepatocytes, ballooning, grade 0. Cytoplasm is pink and granular and liver cells have sharp angles. H&E, X 40. (C) Ballooning, grade 1. Hepatocytes have rounded contours with clear reticular cytoplasm. Size is quite similar to that of normal hepatocytes, H&E, X 40. (D) Ballooning, grade 2. Cells are rounded with clear cytoplasm and twice as large as normal hepatocytes (star), H&E, X 40 Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology. 2012 Nov;56(5):1751-9

Steatosis, Activity, Fibrosis Score Activity grade (A, from 0-4) was the unweighted addition of hepatocyte ballooning (0-2) and lobular inflammation (0-2): Cases with A 0 (A = 0) had no activity, A 1 (A = 1), mild activity, A 2 (A = 2), moderate activity, A 3 (A 3) severe activity. Stage of fibrosis (F) was assessed using the score described by NASH- CRN

Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease Hepatology Volume 60, Issue 2, pages 565-575, 26 JUN 2014 DOI: 10.1002/hep.27173 http://onlinelibrary.wiley.com/doi/10.1002/hep.27173/full#hep27173-fig-0001

Improves interobserver variation. Utility and appropriateness of the Fatty Liver Inhibition of Progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology. 2014; 60: 565 575

Does the SAF predict natural history? After adjustment for fibrosis, the SAF score was not associated with increased mortality in NAFLD. SAF score and mortality in NAFLD after up to 41 years of follow-up. Scand J Gastroenterol. 2016 Sep 10:1-5.

Extending the Ballooning Score Beyond 2: A Proposal for a New Balloon Score AASLD Abstract 2015

A criticism of the NAFLD Activity Score (NAS) has been that it gives less weight to ballooning than to steatosis or lobular inflammation. Beginning in April, 2010 we prospectively classified all biopsies with ballooning as classical (distinct, enlarged, with clumped cytoplasm) or non-classical (cytoplasmic changes without distinctive cytomegaly). Severe ballooning was defined as clusters of classical ballooned cells visible at low magnification. The NASH CRN new balloon score was created by combining the old balloon score and these new characteristics with a final range from 0 to 4.

Conclusions: Compared to cases without ballooning, nonclassical ballooning cases had more severe histology Compared to non-classical ballooning cases, classical ballooning cases had more severe histology Severe ballooning cases differed from nonsevere ballooning in that they had more severe histology

Although distinguishing NASH from NAFLD may still have relevance for clinical practice, we suggest that using this binary classification in clinical research is somewhat artificial. Liver histology and clinical trials for nonalcoholic steatohepatitisperspectives from 2 pathologists. Gastroenterology. 2015 Nov;149(6).

Progression of fibrosis in NAFLD A meta-analysis of studies of paired liver biopsy studies. The annual fibrosis progression rate in patients with NAFL who had stage 0 fibrosis at baseline was 0.07 stages compared with 0.14 stages in patients with NASH. These findings correspond to 1 stage of progression over 14.3 years for patients with NAFLD and 7.1 years for patients with NASH. Liver fibrosis progresses in patients with NAFLD and NASH. Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology 2015;13:643 654

Prognosis of NAFLD NAFLD patients have increased risk of death, with a high risk of death from cardiovascular disease and liver-related disease. The NAS was not able to predict overall mortality, whereas fibrosis stage predicted both overall and disease-specific mortality. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015 May;61(5):1547-54.

Factors determining the prognosis of NAFLD Patients with fibrosis, regardless of steatohepatitis or NAFLD activity score, had shorter survival times than patients without fibrosis. Liver fibrosis, but no other histologic features, associates with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology August 2015 Volume 149, Issue 2, Pages 389 397

Fibrosis stage is the strongest predictor for disease specific mortality in NAFLD after up to 33 years of follow up Hepatology Volume 61, Issue 5, pages 1547-1554, 23 MAR 2015 DOI: 10.1002/hep.27368 http://onlinelibrary.wiley.com/doi/10.1002/hep.27368/full#hep27368-fig-0002

NASH and cardiovascular disease NAFLD is an independent risk factor for atherosclerosis and cardiovascular disease Fatty liver as an independent predictor of early carotid atherosclerosis: results from a large transversal and long-term follow-up J Hepatol, 65 (2016), pp. 95 102 Nonalcoholic fatty liver disease and vascular function: cross-sectional analysis in the Framingham heart study Arterioscler Thromb Vasc Biol, 35 (2015), pp. 1284 1291

Liver Histology and Clinical Trials for Nonalcoholic Steatohepatitis I Fibrosis even, in the earliest recognizable stage, is a more powerful predictor of long-term outcome than other histologic features or diagnostic categorization. Fibrosis is easy to assess histologically and highly reproducible between pathologists. It is a robust criterion provided that the biopsy is adequate (recommended 2- cm core from at least a 16-G needle) and has obvious clinical prognostic value. Liver histology and clinical trials for nonalcoholic steatohepatitis-perspectives from 2 pathologists. Gastroenterology. 2015 Nov;149(6).

Liver Histology and Clinical Trials for Nonalcoholic Steatohepatitis II Fibrosis regression might, therefore, be the best surrogate marker for assessing benefit of a drug. The drawback is that fibrosis regression may need more time to be observed than regression of other inflammatory or hepatocellular lesions and probably would need a larger clinical sample. It is an achievable goal because fibrosis regression was observed in the recent FLINT study over a 72-week period.

Liver Histology and Clinical Trials for Nonalcoholic Steatohepatitis III An expanded semiquantitative fibrosis staging system or a sensitive technique such as morphometry may help to quantify fibrosis regression in even shorter trials, but the amount of collagen loss needed to define a clinically relevant has yet to be defined

Alcoholic Liver Disease

Small droplet fatty change/ Foamy degeneration

Alcoholic foamy degeneration 21 Japanese patients Presented with jaundice and hepatomegaly Reversible Alcoholic foamy degeneration - a pattern of acute alcoholic injury of the liver. Gastroenterology. 1983 Apr;84(4):683-92 Alcoholic Foamy Degeneration and Alcoholic Fatty Liver With Jaundice: Often Overlooked Causes of Jaundice and Hepatic Decompensation That Can Mimic Alcoholic Hepatitis Clinical. Liver Disease, Vol 6, No 6, December 2015

A Histologic Scoring System for Prognosis of Patients With Alcoholic Hepatitis Gastroenterology. 2014 May; 146(5): 1231 1239.

Development of the scoring system The system was developed in a group of 217 patients and a semi-quantitative scoring system was developed, called the alcoholic hepatitis histologic score (AHHS). The system was validated in an independent set of 109 patients.

Histological Features Independently Associated with 90-day survival: A) Hepatocellular and canalicular bilirubinostasis B) Ductular bilirubinostasis C) Megamitochondria D and E) Mild and severe PMN infiltration

Histopathological agreement: Kappa values 0.65 for fibrosis 0.86 for bilirubinostasis 0.60 for neutrophil infiltration and 0.46 for megamitochondria.

Points to note Neutrophil infiltration is associated with a more favorable outcome shifts the paradigm and the authors suggest that patients with active inflammation probably have more regenerative potential Nearly half of the patients with canalicular/ductular bilirubinostasis or hepatocellular plus canalicular/ductular bilirubinostasis developed a bacterial infection during hospitalization

STOPAH 1053 patients were available for the primary end-point analysis. Pentoxifylline did not improve survival in patients with alcoholic hepatitis. Prednisolone was associated with a reduction in 28-day mortality that did not reach significance and with no improvement in outcomes at 90 days or 1 year. Prednisolone or pentoxifylline for alcoholic hepatitis N Engl J Med. 2015 Apr 23;372(17):1619-28.

STOPAH Histology Two pathologists blinded to the clinical details. Biopsies were considered adequate when there were at least 5 portal tracts. They were scored using the Alcoholic Hepatitis Histological Score

STOPAH Histology: Diagnosis of Alcoholic Hepatitis Overall a diagnosis of alcoholic hepatitis was confirmed in 87% of biopsies, overall, 91% obtained within 2 days of starting treatment.

STOPAH Histology Liver histology remains a useful tool in patients presenting with features of alcoholic hepatitis but with diagnostic uncertainty. Where the diagnosis is made clinically with confidence histology will identify 13 % of patients with alternative diagnoses, predominantly that of inactive cirrhosis. Provides independent validation of the AHSS

Other things which have been be done and perhaps we could/ should do: Senescence markers Hepatocyte Expression of the Senescence Marker p21 Is Linked to Fibrosis and an Adverse Liver-Related Outcome in Alcohol-Related Liver Disease. PLOS One September 2013, Volume 8, Issue 9, e72904 Progenitor markers Liver progenitor cell markers correlate with liver damage and predict short-term mortality in patients with alcoholic hepatitis. Hepatology. 2012 Jun;55(6):1931-41. Chemokine expression Hepatic Expression of CXC Chemokines Predicts Portal Hypertension and Survival in Patients With Alcoholic Hepatitis. Gastroenterology. 2009 May;136(5):1639-50. Apoptosis Markers Hepatocyte apoptosis is a pathologic feature of human alcoholic hepatitis. Journal of Hepatology 34 (2001) 248±253 Proliferation makers Hepatic cell proliferation plays a pivotal role in the prognosis of alcoholic hepatitis. Journal of Hepatology 2015 vol. 63 j 609 621 Progenitor cell expansion and impaired hepatocyte regeneration in explanted livers from alcoholic hepatitis. Gut 2015;64:1949 1960.

Fat and liver tumours

HCC in patients with NAFLD In noncirrhotic HCC patients, histological steatosis was frequently present, whereas overt steatohepatitis did not occur. Hepatocellular carcinoma in noncirrhotic livers is associated with steatosis rather than steatohepatitis. Eur J Gastroenterol Hepatol. 2016 Aug;28(8):955-62.

NAFLD-HCC could arise also in the absence of cirrhosis more often detected at a later tumor stage but after patient matching, it has a similar survival rate compared to HCV infection HEPATOLOGY 2016;63:827 838

Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009 Hepatology Volume 62, Issue 6, pages 1723-1730, 24 OCT 2015 DOI: 10.1002/hep.28123 http://onlinelibrary.wiley.com/doi/10.1002/hep.28123/full#hep28123-fig-0003

Hepatocytes tumours that contain intracellular fat multifocal hepatic steatosis, focal nodular hyperplasia (22-85%) adenomas hepatocellular carcinoma Fatty liver deposition and sparing: a pictorial review Insights Imaging. 2011 Oct; 2(5): 533 538.

Fatty change in hepatic adenoma HNF1α mutated adenoma: characteristic: diffuse and homogeneous inflammatory adenoma: 11% of cases: focal and heterogeneous. β-catenin mutated adenoma 21% of cases: diffuse but non-homogeneous

Steatotic HCC Steatotic HCC is a common histological variant of HCC with distinct association with underlying fatty liver, steatohepatitis and metabolic risks. Despite more favourable baseline tumour features, it was associated with late tumour relapse. Steatotic hepatocellular carcinoma: a variant associated with metabolic factors and late tumour relapse. Histopathology 2016

Steatotic hepatocellular carcinoma: a variant associated with metabolic factors and late tumour relapse Histopathology 9 SEP 2016 DOI: 10.1111/his.13029 http://onlinelibrary.wiley.com/doi/10.1111/his.13029/full#his13029-fig-0001